Law Firm Investigating Possible Gadolinium Litigation

(PRLEAP.COM) The Rasansky Law Firm is investigating possible Gadolinium litigation in light of a recent public health advisory by the Food and Drug Administration. The FDA published an alert showing a possible link between Gadolinium, a heavy metal used in MRI and MRA contrasting agents, with a disease called Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermotherapy (NFD).

According to the FDA, the problem has so far been found only in instances of "off-label" used of the Contrasting agent for MRA, or Magnetic Resonance Angiography. "Off-label" means the drug has not been approved by the FDA for a particular use, which might be dangerous given that often 3 times the FDA approved dose is used during an MRA.

"Gadolinium is supposed to secrete out of the body quickly", says lawyer Jeff Rasansky, of the Rasansky Law Firm, "but, according to preliminary FDA reports, it looks like people with impaired kidney function might not be able to secrete the toxic substance out of the body quickly enough to avoid suffering lifelong impairment from Gadolinium".

The Rasasnky Law Firm will be closely monitoring FDA announcements concerning the Gadolinium-based contrasting agents Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance to determine whether litigation is necessary to protect the rights of people injured by the contrasting agents.

The Law Firm is also currently reviewing the cases of victims of NSF/NFD to determine whether individuals have a legal case against the makers of Gadolinium based contrasting agents. Individuals diagnosed with Nephrogenic Systemic Fibrosis (NSF) or Nephrogenic Fibrosing Dermotherapy (NFD) are encouraged to contact the Rasansky Law Firm so we may begin investigating your case.

PR Leap is a service of Condesa, Inc. © 2009 All Rights Reserved. Use of our service is governed by our Privacy Policy and Terms of Service.
Issuers of news releases are solely responsible for the accuracy of their content. Copyright / IP Policy